StockData

Viridian Therapeutics, Inc.\DE vs vTv Therapeutics

VRDN and VTVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VRDN and VTVT compare

Viridian Therapeutics, Inc.\DE is the larger company, worth 50 times as much as vTv Therapeutics ($3.4B against $68.4M).

vTv Therapeutics grew revenue faster over the last twelve months (216600% versus 23220% for Viridian Therapeutics, Inc.\DE).

vTv Therapeutics keeps more of each dollar of sales as profit, with a net margin of −12.9% compared with −544% at Viridian Therapeutics, Inc.\DE.

vTv Therapeutics scores higher on the StockData Score (11 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVRDNVTVT
Size and price
Market cap$3.4B$68.4M
Share price$30.06$17.29
Change, 1 year4.5%−43.9%
Change, 5 years64.3%−67.7%
Beta (5Y)−0.130.08
Employees25226
StockData Score
Total score411 (better)
Valuation score03 (better)
Growth score2 (better)1
Performance score12 (better)
Health score15 (better)
Dividend score00
Valuation
P/S47.9×1.9× (better)
P/B5.1×0.9× (better)
FCF yield−9.8%–
Fair value$8.47$44.97
Margin of safety−255%61.6% (better)
Growth
Revenue growth (TTM)23220%216600% (better)
Revenue growth, 5Y average132%–
Profitability
Operating margin−570%−25.1% (better)
Net margin−544%−12.9% (better)
FCF margin−471%–
Return on equity−65.7%−11.7% (better)
Financial health
Debt / equity–0.00
Interest coverage−26.0×–
Current ratio16.95 (better)12.48
Altman Z-score2.65 (better)0.71
Piotroski F-score44
Dividends and buybacks
Buyback yield−1.7%–
Shareholder yield−1.7%0.00% (better)
Ownership
Held by institutions120%40.6%
Held by insiders21.8%26.3%
Insider net buying, 12 months$19.6M–
Short interest, % of float19.2%5.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.